127 related articles for article (PubMed ID: 29856019)
1. Neurophysiological Assessment of Huntington's Disease Model Mice.
Donzis EJ; Holley SM; Cepeda C; Levine MS
Methods Mol Biol; 2018; 1780():163-177. PubMed ID: 29856019
[TBL] [Abstract][Full Text] [Related]
2. Enhanced striatopallidal gamma-aminobutyric acid (GABA)
Perez-Rosello T; Gelman S; Tombaugh G; Cachope R; Beaumont V; Surmeier DJ
Mov Disord; 2019 May; 34(5):684-696. PubMed ID: 30726572
[TBL] [Abstract][Full Text] [Related]
3. Alterations of striatal indirect pathway neurons precede motor deficits in two mouse models of Huntington's disease.
Sebastianutto I; Cenci MA; Fieblinger T
Neurobiol Dis; 2017 Sep; 105():117-131. PubMed ID: 28578004
[TBL] [Abstract][Full Text] [Related]
4. Differential electrophysiological and morphological alterations of thalamostriatal and corticostriatal projections in the R6/2 mouse model of Huntington's disease.
Parievsky A; Moore C; Kamdjou T; Cepeda C; Meshul CK; Levine MS
Neurobiol Dis; 2017 Dec; 108():29-44. PubMed ID: 28757327
[TBL] [Abstract][Full Text] [Related]
5. Motor Assessment in Huntington's Disease Mice.
Dunnett SB; Brooks SP
Methods Mol Biol; 2018; 1780():121-141. PubMed ID: 29856017
[TBL] [Abstract][Full Text] [Related]
6. Impaired development of cortico-striatal synaptic connectivity in a cell culture model of Huntington's disease.
Buren C; Parsons MP; Smith-Dijak A; Raymond LA
Neurobiol Dis; 2016 Mar; 87():80-90. PubMed ID: 26711622
[TBL] [Abstract][Full Text] [Related]
7. Time course of early motor and neuropathological anomalies in a knock-in mouse model of Huntington's disease with 140 CAG repeats.
Menalled LB; Sison JD; Dragatsis I; Zeitlin S; Chesselet MF
J Comp Neurol; 2003 Oct; 465(1):11-26. PubMed ID: 12926013
[TBL] [Abstract][Full Text] [Related]
8. Cortico-Striatal Cross-Frequency Coupling and Gamma Genesis Disruptions in Huntington's Disease Mouse and Computational Models.
Naze S; Humble J; Zheng P; Barton S; Rangel-Barajas C; Rebec GV; Kozloski JR
eNeuro; 2018; 5(6):. PubMed ID: 30627632
[TBL] [Abstract][Full Text] [Related]
9. Brain urea increase is an early Huntington's disease pathogenic event observed in a prodromal transgenic sheep model and HD cases.
Handley RR; Reid SJ; Brauning R; Maclean P; Mears ER; Fourie I; Patassini S; Cooper GJS; Rudiger SR; McLaughlan CJ; Verma PJ; Gusella JF; MacDonald ME; Waldvogel HJ; Bawden CS; Faull RLM; Snell RG
Proc Natl Acad Sci U S A; 2017 Dec; 114(52):E11293-E11302. PubMed ID: 29229845
[TBL] [Abstract][Full Text] [Related]
10. Riluzole prolongs survival time and alters nuclear inclusion formation in a transgenic mouse model of Huntington's disease.
Schiefer J; Landwehrmeyer GB; Lüesse HG; Sprünken A; Puls C; Milkereit A; Milkereit E; Kosinski CM
Mov Disord; 2002 Jul; 17(4):748-57. PubMed ID: 12210870
[TBL] [Abstract][Full Text] [Related]
11. Alterations in N-methyl-D-aspartate receptor sensitivity and magnesium blockade occur early in development in the R6/2 mouse model of Huntington's disease.
Starling AJ; André VM; Cepeda C; de Lima M; Chandler SH; Levine MS
J Neurosci Res; 2005 Nov; 82(3):377-86. PubMed ID: 16211559
[TBL] [Abstract][Full Text] [Related]
12. Altered excitatory and inhibitory inputs to striatal medium-sized spiny neurons and cortical pyramidal neurons in the Q175 mouse model of Huntington's disease.
Indersmitten T; Tran CH; Cepeda C; Levine MS
J Neurophysiol; 2015 Apr; 113(7):2953-66. PubMed ID: 25673747
[TBL] [Abstract][Full Text] [Related]
13. A whole brain longitudinal study in the YAC128 mouse model of Huntington's disease shows distinct trajectories of neurochemical, structural connectivity and volumetric changes.
Petrella LI; Castelhano JM; Ribeiro M; Sereno JV; Gonçalves SI; Laço MN; Hayden MR; Rego AC; Castelo-Branco M
Hum Mol Genet; 2018 Jun; 27(12):2125-2137. PubMed ID: 29668904
[TBL] [Abstract][Full Text] [Related]
14. Synaptic scaling up in medium spiny neurons of aged BACHD mice: A slow-progression model of Huntington's disease.
Rocher AB; Gubellini P; Merienne N; Boussicault L; Petit F; Gipchtein P; Jan C; Hantraye P; Brouillet E; Bonvento G
Neurobiol Dis; 2016 Feb; 86():131-9. PubMed ID: 26626081
[TBL] [Abstract][Full Text] [Related]
15. The mGluR5 positive allosteric modulator, CDPPB, ameliorates pathology and phenotypic signs of a mouse model of Huntington's disease.
Doria JG; de Souza JM; Andrade JN; Rodrigues HA; Guimaraes IM; Carvalho TG; Guatimosim C; Dobransky T; Ribeiro FM
Neurobiol Dis; 2015 Jan; 73():163-73. PubMed ID: 25160573
[TBL] [Abstract][Full Text] [Related]
16. Mouse Models of Huntington's Disease.
Farshim PP; Bates GP
Methods Mol Biol; 2018; 1780():97-120. PubMed ID: 29856016
[TBL] [Abstract][Full Text] [Related]
17. Deficits of glutamate transmission in the striatum of toxic and genetic models of Huntington's disease.
Rossi S; Prosperetti C; Picconi B; De Chiara V; Mataluni G; Bernardi G; Calabresi P; Centonze D
Neurosci Lett; 2006 Dec; 410(1):6-10. PubMed ID: 17070651
[TBL] [Abstract][Full Text] [Related]
18. AMPK-α1 functions downstream of oxidative stress to mediate neuronal atrophy in Huntington's disease.
Ju TC; Chen HM; Chen YC; Chang CP; Chang C; Chern Y
Biochim Biophys Acta; 2014 Sep; 1842(9):1668-80. PubMed ID: 24946181
[TBL] [Abstract][Full Text] [Related]
19. Inhibition of apoptosis signal-regulating kinase 1 reduces endoplasmic reticulum stress and nuclear huntingtin fragments in a mouse model of Huntington disease.
Cho KJ; Lee BI; Cheon SY; Kim HW; Kim HJ; Kim GW
Neuroscience; 2009 Nov; 163(4):1128-34. PubMed ID: 19646509
[TBL] [Abstract][Full Text] [Related]
20. Cellular Analysis of Silencing the Huntington's Disease Gene Using AAV9 Mediated Delivery of Artificial Micro RNA into the Striatum of Q140/Q140 Mice.
Keeler AM; Sapp E; Chase K; Sottosanti E; Danielson E; Pfister E; Stoica L; DiFiglia M; Aronin N; Sena-Esteves M
J Huntingtons Dis; 2016 Oct; 5(3):239-248. PubMed ID: 27689620
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
